New pill targets Hard-to-Treat cancers with PIK3CA mutation
NCT ID NCT07524322
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing an experimental oral drug called RGT-490 in about 63 adults with advanced solid tumors (including certain breast, ovarian, and endometrial cancers) that have a PIK3CA gene mutation and have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RGT-490 (oral tablet)
What this could lead to
If successful, this could point toward a new treatment option for people with certain hard-to-treat cancers that have a PIK3CA mutation.
What could go wrong
This is a very early (Phase 1) study with only 63 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NEXT Houston
RECRUITINGHouston, Texas, 77054, United States
-
NEXT San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
START Los Angeles
RECRUITINGLos Angeles, California, 90025, United States